ライフサイエンスコーパス: phosphodiesterase 4

1 1 is mediated by PA-dependent modulation of phosphodiesterase 4.

2 lopment for COPD; they include inhibitors of phosphodiesterase 4.

3 uggest a target for anti-HIV-1 chemotherapy, phosphodiesterase 4.

4 tion of phosphodiesterase 3B, in addition to phosphodiesterase 4D.

5 Human trabecular meshwork cells express phosphodiesterase 4, 5, and 7 gene family isoforms and e

6 Messenger RNA transcripts for phosphodiesterase 4, 5, and 7 isozymes were isolated in

7 P elevations in the PFC secondary to reduced phosphodiesterase 4 activity present in Disc1 deficiency

8 sine monophosphate levels through changes in phosphodiesterase-4D activity, and these effects are ind

9 trabecular meshwork cells only isozymes for phosphodiesterase 4 and 5 isozymes were detected.

10 ing the rolipram-sensitive cyclic nucleoside phosphodiesterase 4 and resulted in increased susceptibi

11 zing PA, which is an allosteric activator of phosphodiesterase 4 and the molecular target of rapamyci

12 UD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inh

13 atory mediators, that is, dimethyl fumarate, phosphodiesterase 4, and leukotriene B4 inhibitors in pe

14 t, one genomewide significant hit located in phosphodiesterase 4D, cAMP-specif (PDE4D) and 26 SNPs wi

15 The phosphodiesterase 4D, cAMP-specific (phosphodiesterase E

16 Phosphodiesterase 4 catalyzes the hydrolysis of cyclic A

17 ic adenosine monophosphate levels, increased phosphodiesterase-4 enzymatic activity, and phosphodiest

18 Inhibition of phosphodiesterase 4 extends beta(2)AR-induced PKA activi

19 al infarction and stroke and PDE4D (encoding phosphodiesterase 4D) for ischemic stroke.

20 association between polymorphisms within the phosphodiesterase 4D gene (PDE4D) and ischemic stroke wa

21 ble small molecule that specifically targets phosphodiesterase-4, in the treatment of active psoriati

22 The phosphodiesterase 4 inhibitor roflumilast N-oxide (RNO)

23 we demonstrate that brief treatment with the phosphodiesterase 4 inhibitor rolipram ameliorates defic

24 Roflumilast, a selective phosphodiesterase 4 inhibitor, has been shown to provide

25 occluded by PKA activator, and prevented by phosphodiesterase 4 inhibitor.

26 of M. tuberculosis infected rabbits with the phosphodiesterase-4 inhibitor CC-3052 plus isoniazid sig

27 The phosphodiesterase-4 inhibitor roflumilast can improve lu

28 ions or treatment with the anti-inflammatory phosphodiesterase-4 inhibitor roflumilast prevents COPD-

29 ted after treatment before training with the phosphodiesterase-4 inhibitor rolipram (0.1 mg/kg, i.p.)

30 act of adjunctive immune modulation, using a phosphodiesterase-4 inhibitor that dampens the innate im

31 Apremilast is an oral phosphodiesterase-4 inhibitor that modulates several inf

32 compounds, similar to thalidomide, were not phosphodiesterase 4 inhibitors and markedly stimulated T

33 ibitory drugs (SelCIDs) are a novel class of phosphodiesterase 4 inhibitors discovered during a thali

34 : one class of compounds, shown to be potent phosphodiesterase 4 inhibitors, inhibited TNF-alpha prod

35 ls, including macrolides, CXCR2 antagonists, phosphodiesterase 4 inhibitors, p38 mitogen-activating p

36 optimization of a series of 1,7-napthyridine phosphodiesterase-4 inhibitors is described.

37 pical agents such as tacrolimus ointment and phosphodiesterase-4 inhibitors offers new approaches dir

38 Further analysis reveals that phosphodiesterase 4 is the major family that shapes PKA

39 therapies that target AKT, protein kinase C, phosphodiesterase 4, mammalian target of rapamycin, hist

40 therefore explored if BPN14770, a prototypic phosphodiesterase-4D negative allosteric modulator (PDE4

41 acterized enzyme, nucleotide pyrophosphatase/phosphodiesterase-4 (NPP4), as a potent hydrolase of Ap3

42 flammatory treatments, such as inhibitors of phosphodiesterase 4 or nuclear factor kappaB, although t

43 so in development, and include inhibitors of phosphodiesterase-4, p38 mitogen-activated protein kinas

44 lidin ecarboxylate (1), a novel inhibitor of phosphodiesterase 4 (PDE 4), were investigated.

45 lular signal-regulated kinase (ERK)-mediated phosphodiesterase 4 (PDE4) activation and accompanied by

46 premilast), a novel potent and orally active phosphodiesterase 4 (PDE4) and tumor necrosis factor-alp

47 e naive CD4+ T cells, express high levels of phosphodiesterase 4 (PDE4) constitutively.

48 The phosphodiesterase 4 (PDE4) family coordinates the degrad

49 Members of the cAMP-specific phosphodiesterase 4 (PDE4) family, which contains >25 di

50 Inhibition of cyclic AMP (cAMP)-specific phosphodiesterase 4 (PDE4) has been proposed as a potent

51 Phosphodiesterase 4 (PDE4) has four isoforms (PDE4A-D) w

52 Phosphodiesterase 4 (PDE4) inhibition restores the suppr

53 We now show that the phosphodiesterase 4 (PDE4) inhibitor rolipram (which rea

54 w (PLY), reduced it when co-applied with the phosphodiesterase 4 (PDE4) inhibitor rolipram.

55 loped to enhance the targeting efficiency of phosphodiesterase 4 (PDE4) inhibitor to the lungs for tr

56 Crisaborole, a topical phosphodiesterase 4 (PDE4) inhibitor, became available i

57 wo phase III clinical studies found that the phosphodiesterase 4 (PDE4) inhibitor, roflumilast, reduc

58 time the therapeutic potential of a specific phosphodiesterase 4 (PDE4) inhibitor, rolipram, with ant

59 Development of orally available phosphodiesterase 4 (PDE4) inhibitors as anti-inflammato

60 Oral phosphodiesterase 4 (PDE4) inhibitors, such as cilomilas

61 Phosphodiesterase 4 (PDE4) is a key cAMP-metabolizing en

62 Phosphodiesterase 4 (PDE4) is an essential contributor t

63 is tightly controlled by negative regulator phosphodiesterase 4 (PDE4) that hydrolyzes cAMP.

64 sed drug screen and discovered inhibitors of phosphodiesterase 4 (PDE4) to be particularly effective

65 Inhibition of phosphodiesterase 4 (PDE4) to increase endothelial cAMP

66 scaffolding protein DISC1 and cAMP-degrading phosphodiesterase 4 (PDE4) to regulate PDE4 activity.

67 We tested the hypothesis that inhibition of phosphodiesterase 4 (PDE4) with rolipram to increase vas

68 ed a dynamical model to study the effects of phosphodiesterase 4 (PDE4), a cAMP phosphodiesterase tha

69 and increased activity and protein levels of phosphodiesterase 4 (PDE4), an enzyme that degrades cAMP

70 ed to a dual inhibition of p38alpha MAPK and phosphodiesterase 4 (PDE4), and the potential benefits a

71 and that activated Erk transiently inhibits phosphodiesterase 4 (PDE4), the enzyme that hydrolyzes c

72 Phosphodiesterase 4 (PDE4), the major cAMP-specific PDE

73 Phosphodiesterase 4 (PDE4), the primary cAMP-hydrolyzing

74 ia 1 (DISC1) and the cAMP-hydrolyzing enzyme phosphodiesterase 4 (PDE4).

75 We found that the phosphorylation of phosphodiesterase-4 (PDE4) by cyclin-dependent protein k

76 ctivity by using (11)C-(R)-rolipram to image phosphodiesterase-4 (PDE4) in unmedicated MDD patients a

77 ctivity by using (11)C-(R)-rolipram to image phosphodiesterase-4 (PDE4) in unmedicated MDD patients a

78 8a was selected as a selective submicromolar phosphodiesterase-4 (PDE4) inhibitor associated with ant

79 together with the specific cyclic AMP (cAMP) phosphodiesterase-4 (PDE4) inhibitor rolipram, but not t

80 Here we investigated whether 3 phosphodiesterase-4 (PDE4) inhibitors (rolipram, roflumi

81 Phosphodiesterase-4 (PDE4) inhibitors have the potential

82 Cyclic nucleotide phosphodiesterase-4 (PDE4) is a component of signaling p

83 ed with a profound up-regulation of specific phosphodiesterase-4 (PDE4) isoforms because of increased

84 Phosphodiesterase-4 (PDE4) plays an important role in me

85 bit neutrophilic inflammation; inhibitors of phosphodiesterase-4 (PDE4), p38 mitogen-activated protei

86 for inhibitory activity toward cAMP-specific phosphodiesterase-4 (PDE4).

87 Here we show that phosphodiesterase 4D (PDE4D) acts downstream of Neuropil

88 utative candidate genes for ischemic stroke: phosphodiesterase 4D (PDE4D) and 5-lipoxygenase activati

89 ive regulation of cAMP-specific 3',5'-cyclic phosphodiesterase 4D (PDE4D) and the regulatory subunit

90 Here, we show that phosphodiesterase 4D (PDE4D) selectively impacts signali

91 ATF4 binding region in the genomic locus of phosphodiesterase 4D (PDE4D), a gene implicated in psych

92 proteosomal degradation of cAMP-hydrolyzing phosphodiesterase 4D (PDE4D).

93 phosphodiesterase-4 enzymatic activity, and phosphodiesterase-4D (PDE4D) isoform-specific messenger

94 t on NMDAR expression and function through a phosphodiesterase 4/PKA/CREB-dependent mechanism, which

95 vators of adenylate cyclase or inhibitors of phosphodiesterase 4) promoted degradation of short-lived

96 ically determined, and compounds that affect phosphodiesterase 4, protein kinase A, and cAMP producti

97 ocal protein kinase A-mediated activation of phosphodiesterase 4 resulting in hypophosphorylated phos

98 intact human cells, selective inhibitors for phosphodiesterase 4 (rolipram) and 5 (E4021) gene famili

99 ed region of recombinant human cAMP-specific phosphodiesterase 4 subtype A (rhPDE4A), we engineered t

100 d were enhanced by rolipram, an inhibitor of phosphodiesterase 4, suggesting that the antiproliferati

101 containing PKA, PKC, calmodulin, and PDE4D (phosphodiesterase 4D) to the beta2-adrenergic receptor.

102 4D, which encodes cyclic AMP (cAMP)-specific phosphodiesterase 4D, were found to be heterozygous in t